Lista de obras -

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

artículo científico publicado en 2015

A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors

artículo científico publicado en 2017

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer ⬇️

artículo científico publicado el 19 de abril de 2013

A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

artículo científico publicado en 2014

A role for the amino terminus of human topoisomerase I ⬇️

artículo científico publicado el 1 de enero de 1998

Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens

artículo científico publicado en 2017

Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer

artículo científico publicado en 2020

Can we unlock the potential of IGF-1R inhibition in cancer therapy?

artículo científico publicado en 2014

Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes

artículo científico publicado en 2017

Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft

artículo científico publicado en 2015

Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials ⬇️

artículo científico publicado el 7 de marzo de 2013

Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE)

scientific article published on 17 June 2020

Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth

scientific article published on 15 October 2013

Epithelial ovarian cancer experimental models.

artículo científico publicado en 2013

Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts

article

High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome.

scientific article published on 02 March 2016

High-performance liquid chromatographic quantitation of total and lactone 20(S)camptothecin in patients receiving oral 20(S)camptothecin ⬇️

artículo científico publicado el 10 de abril de 1998

Hormone response in ovarian cancer: time to reconsider as a clinical target?

artículo científico publicado en 2012

IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors ⬇️

artículo científico publicado el 27 de enero de 2012

In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.

artículo científico publicado en 2016

Insulin-like growth factor pathway ⬇️

artículo científico publicado el 1 de diciembre de 2010

Interaction between the N-terminus of human topoisomerase I and SV40 large T antigen ⬇️

artículo científico publicado el 1 de abril de 1998

North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study

artículo científico publicado en 2014

Novel pharmacological agents in clinical development for solid tumours ⬇️

artículo científico publicado el 1 de diciembre de 2001

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer

artículo científico publicado en 2014

Patient-derived xenograft models in gynecologic malignancies

artículo científico publicado en 2014

Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment

artículo científico publicado en 2013

Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer

scientific article published on 21 November 2019

Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.

artículo científico publicado en 2017

Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors

artículo científico publicado en 2014

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer

artículo científico publicado en 2010

Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma ⬇️

artículo científico publicado el 22 de abril de 2011

Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts

artículo científico publicado en 2017

Quantifying insulin receptor isoform expression in FFPE breast tumors ⬇️

artículo científico publicado el 30 de abril de 2012

Recurrent basal cell carcinoma: a clinicopathological study and evaluation of histomorphological findings in primary and recurrent lesions

artículo científico publicado el 1 de junio de 2011

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer

artículo científico publicado en 2016

The Insulin-Like Growth Factor System in Cancer ⬇️

artículo científico publicado el 1 de junio de 2012

Tumorgrafts as in vivo surrogates for women with ovarian cancer.

artículo científico publicado en 2014

Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment

artículo científico publicado en 2015

Lista de obras de

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer ⬇️

A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

A role for the amino terminus of human topoisomerase I ⬇️

Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens

Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer

Can we unlock the potential of IGF-1R inhibition in cancer therapy?

Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes

Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft

Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials ⬇️

Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE)

Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth

Epithelial ovarian cancer experimental models.

Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts

High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome.

High-performance liquid chromatographic quantitation of total and lactone 20(S)camptothecin in patients receiving oral 20(S)camptothecin ⬇️

Hormone response in ovarian cancer: time to reconsider as a clinical target?

IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors ⬇️

In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.

Insulin-like growth factor pathway ⬇️

Interaction between the N-terminus of human topoisomerase I and SV40 large T antigen ⬇️

North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study

Novel pharmacological agents in clinical development for solid tumours ⬇️

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer

Patient-derived xenograft models in gynecologic malignancies

Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment

Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer

Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.

Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer

Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma ⬇️

Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts

Quantifying insulin receptor isoform expression in FFPE breast tumors ⬇️

Recurrent basal cell carcinoma: a clinicopathological study and evaluation of histomorphological findings in primary and recurrent lesions

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer

The Insulin-Like Growth Factor System in Cancer ⬇️

Tumorgrafts as in vivo surrogates for women with ovarian cancer.

Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment